| Literature DB >> 29360137 |
Elizabeth Brunt1, Shinichi Aishima2, Pierre-Alain Clavien3, Kathryn Fowler4, Zachary Goodman5, Gregory Gores6, Annette Gouw7, Alex Kagen8, David Klimstra9, Mina Komuta10, Fukuo Kondo11, Rebecca Miksad12, Masayuki Nakano13, Yasuni Nakanuma14, Irene Ng15, Valerie Paradis16, Young Nyun Park17, Alberto Quaglia18, Massimo Roncalli19, Tania Roskams20, Michiie Sakamoto21, Romil Saxena22, Christine Sempoux23, Claude Sirlin24, Ashley Stueck25, Swan Thung26, W M S Tsui27, Xin-Wei Wang28, Aileen Wee29, Hirohisa Yano30, Matthew Yeh31, Yoh Zen32, Jessica Zucman-Rossi33, Neil Theise34.
Abstract
Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been referred to as "combined (or mixed) hepatocellular-cholangiocarcinoma." These tumors, although described over 100 years ago, have attracted greater attention recently because of interest in possible stem cell origin and perhaps because of greater frequency and clinical recognition. Currently, because of a lack of common terminology in the literature, effective treatment and predictable outcome data have been challenging to accrue. This article represents a consensus document from an international community of pathologists, radiologists, and clinicians who have studied and reported on these tumors and recommends a working terminology for diagnostic and research approaches for further study and evaluation.Entities:
Mesh:
Year: 2018 PMID: 29360137 PMCID: PMC6340292 DOI: 10.1002/hep.29789
Source DB: PubMed Journal: Hepatology ISSN: 0270-9139 Impact factor: 17.425